Holen Sie sich die Stockscreener-App
3.4815
3.01%
0.0915
Schlusskurs vom Vortag:
$3.39
Offen:
$3.46
24-Stunden-Volumen:
5,507
Relative Volume:
0.02
Marktkapitalisierung:
$88.54M
Einnahmen:
$247.99M
Nettoeinkommen (Verlust:
$-521.97M
KGV:
-3.1365
EPS:
-1.11
Netto-Cashflow:
$-194.28M
1W Leistung:
-14.39%
1M Leistung:
+1.19%
6M Leistung:
-64.90%
1J Leistung:
-76.06%
1-Tages-Spanne:
$3.46
$3.46
1-Wochen-Bereich:
$3.37
$4.18
52-Wochen-Spanne:
$2.655
$16.52
23 Andme Holding Co Stock (ME) Company Profile
Firmenname
23 Andme Holding Co
Sektor
Branche
Telefon
(650) 938-6300
Adresse
223 N. MATHILDA AVE., SUNNYVALE
Vergleichen Sie ME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ME
23 Andme Holding Co
|
3.46 | 88.54M | 247.99M | -521.97M | -194.28M | -1.11 |
|
TMO
Thermo Fisher Scientific Inc
|
560.80 | 213.05B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
241.07 | 171.63B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
145.84 | 40.96B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
198.40 | 35.93B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
428.76 | 34.28B | 3.84B | 866.24M | 792.60M | 10.37 |
23 Andme Holding Co Stock (ME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-09-22 | Eingeleitet | Cowen | Outperform |
| 2021-11-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-12 | Eingeleitet | Citigroup | Buy |
23 Andme Holding Co Aktie (ME) Neueste Nachrichten
Jane Street Group LLC Sells 1,561,678 Shares of 23andMe Holding Co. (NASDAQ:ME) - MarketBeat
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology - The Manila Times
23andMe Launches Discover23 to Help Accelerate Large-Scale - GlobeNewswire
23andMe Launches Discover23 Platform with Massive 4.7B Genetic Data Points for Medical Research - StockTitan
23andMe (NASDAQ:ME) Stock Price Down 0.3%Should You Sell? - MarketBeat
3 Promising US Penny Stocks With Over $9M Market Cap - Yahoo Finance
YourUpdateTV speaks with Marisa Brahney - GlobeNewswire Inc.
23andMe Holding Co. (NASDAQ:ME) Short Interest Down 16.6% in November - MarketBeat
23andMe Stock Price Prediction: 2024, 2025, 2030 - Benzinga
23Andme Holding Co earnings missed by $2.16, revenue topped estimates - Investing.com Nigeria
US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St
Wojcicki ‘Committed’ to Taking 23andMe Private as Board Quits - MSN
23andMe (NASDAQ:ME) Trading 13.1% HigherHere's Why - MarketBeat
23andMe CEO Anne Wojcicki responds to critics, shares plan for company's future: "Essential for us to restructure" - CBS News
23andMe’s stock falls after company says there’s substantial doubt it can stay in business - MSN
23andMe shares dip as Q2 loss widens despite revenue beat By Investing.com - Investing.com Nigeria
Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential? - Insider Monkey
Struggling 23andMe Is Exploring Splitting the DNA Company in Two - MSN
23andMe inks research deal with Mirador Therapeutics By Investing.com - Investing.com Canada
23andMe to slash 40% of its workforce, end therapeutics program to cut costs - MSN
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation - The Manila Times
23andMe inks research deal with Mirador Therapeutics - Investing.com India
23andMe and Mirador Therapeutics Enter Into Strategic - GlobeNewswire
23andMe Partners with Mirador in Major Drug Development Collaboration | ME Stock News - StockTitan
23andMe Holding Co. (ME) Quarterly 10-Q Report - Quartz
Earnings call: 23andMe announces restructuring and focus shift By Investing.com - Investing.com Australia
Earnings call: 23andMe announces restructuring and focus shift - Investing.com
23andMe Holding Co. (NASDAQ:ME) Q2 2025 Earnings Call Transcript - Insider Monkey
23andMe Reports Improved Financial Metrics Amid Revenue Decline - TipRanks
23andMe cuts 40% of its workforce - Fox Business
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs - Yahoo Finance
23andMe’s stock turns lower after company posts its latest quarterly loss - MSN
23andMe cuts 40% of its workforce, discontinues all therapy programs - Reuters
23andMe to Explore Strategic Alternatives - Marketscreener.com
23andMe Holding Co Reports Q2 FY25 Revenue of $44 Million, Missi - GuruFocus.com
23andMe Holding Co. (ME) Misses Q2 EPS by 216c - StreetInsider.com
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results - GlobeNewswire
23andMe Holding Co. Announces Reduce Overall Headcount - Marketscreener.com
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future - The Manila Times
23andMe Announces Business Restructuring to Streamline - GlobeNewswire
23andMe Cuts 40% of Workforce, Exits Therapeutics in Major Cost-Saving Overhaul | ME Stock News - StockTitan
Earnings Outlook For 23andMe Holding - Benzinga
Federal law could prevent your 23andMe data deletion, but you should still try - Android Police
CORRECTION23andMe to Report Q2 FY2025 Financial Results - The Manila Times
23andMe Revises Q2 FY2025 Earnings Release Time to Pre-Market on Nov 12 | ME Stock News - StockTitan
Finanzdaten der 23 Andme Holding Co-Aktie (ME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):